This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Indian pharma firms cleared by court to export generics of Bayer-patented drugs

( March 9, 2017, 06:28 GMT | Insight) -- The Delhi High Court has ruled in favor in a case involving Indian pharma firms Alembic and Natco Pharmaceuticals, allowing them to export generic versions of Bayer-patented drugs, the Economic Times reports. TThe Delhi High Court has ruled in favor in a case involving Indian pharma firms Alembic and Natco Pharmaceuticals, allowing them to export generic versions of Bayer-patented drugs, the Economic Times reports. German drugs giant Bayer had asked the court in 2016 to stop Alembic from exporting a generic version of blood thinner Xarelto (Rivaroxaban), and in 2014 had sued the government over Natco's export of a generic version of cancer drug Nexavar (Sorafenib). The court found that the generics had been exported for research and regulatory purposes, not for commercial ends. Exporting drugs for R&D was a recognized exception under the WTO Trade-Related Aspects of Intellectual Property Rights, and prohibiting it would stunt industry growth, the court said.  ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections